Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Acquired by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 2.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 6,897 shares of the company’s stock after acquiring an additional 148 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Medpace were worth $2,114,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. RiverPark Advisors LLC purchased a new position in shares of Medpace during the fourth quarter worth $26,000. Contravisory Investment Management Inc. acquired a new stake in Medpace during the 4th quarter worth about $26,000. FinTrust Capital Advisors LLC purchased a new position in shares of Medpace during the 3rd quarter valued at about $30,000. McGlone Suttner Wealth Management Inc. purchased a new position in shares of Medpace during the 4th quarter valued at about $33,000. Finally, IFP Advisors Inc lifted its holdings in shares of Medpace by 144.3% in the 3rd quarter. IFP Advisors Inc now owns 171 shares of the company’s stock valued at $41,000 after buying an additional 101 shares during the period. Institutional investors and hedge funds own 77.98% of the company’s stock.

Insider Buying and Selling

In other news, CEO August J. Troendle sold 100,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $412.98, for a total value of $41,298,000.00. Following the transaction, the chief executive officer now owns 4,833,019 shares in the company, valued at $1,995,940,186.62. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Medpace news, major shareholder Medpace Investors, Llc sold 50,000 shares of the firm’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $391.75, for a total value of $19,587,500.00. Following the transaction, the insider now owns 5,539,947 shares in the company, valued at approximately $2,170,274,237.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO August J. Troendle sold 100,000 shares of the firm’s stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $412.98, for a total value of $41,298,000.00. Following the completion of the transaction, the chief executive officer now owns 4,833,019 shares in the company, valued at approximately $1,995,940,186.62. The disclosure for this sale can be found here. In the last three months, insiders have sold 189,340 shares of company stock worth $76,651,647. Insiders own 20.30% of the company’s stock.

Medpace Price Performance

Medpace stock opened at $407.15 on Wednesday. Medpace Holdings, Inc. has a 12 month low of $187.03 and a 12 month high of $419.42. The stock has a market capitalization of $12.61 billion, a PE ratio of 45.85, a price-to-earnings-growth ratio of 1.97 and a beta of 1.38. The business has a 50 day simple moving average of $397.68 and a 200-day simple moving average of $323.14.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Monday, April 22nd. The company reported $3.20 EPS for the quarter, topping the consensus estimate of $2.45 by $0.75. Medpace had a net margin of 15.00% and a return on equity of 63.98%. The company had revenue of $511.00 million during the quarter, compared to analyst estimates of $512.39 million. The firm’s revenue was up 17.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.27 EPS. On average, equities research analysts anticipate that Medpace Holdings, Inc. will post 10.53 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

MEDP has been the topic of several analyst reports. StockNews.com raised Medpace from a “hold” rating to a “buy” rating in a report on Tuesday. UBS Group raised shares of Medpace from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $282.00 to $452.00 in a research note on Thursday, February 15th. Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and lifted their target price for the company from $340.00 to $450.00 in a report on Tuesday. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Medpace in a report on Monday, March 18th. They set a “hold” rating and a $395.00 price target on the stock. Finally, Robert W. Baird lifted their price objective on shares of Medpace from $312.00 to $408.00 and gave the company an “outperform” rating in a report on Wednesday, February 14th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $395.60.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.